Verastem

Yahoo Finance • 4 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, October 07, 2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval

Verastem Inc., a biopharmaceutical company, reported its financial results for the second quarter of 2025, highlighting a net product revenue of $2.1 million following the launch of its new cancer therapy. Despite a non-GAAP adjusted net l... Full story

Yahoo Finance • 3 months ago

Verastem stock rises after LGSOC treatment data published in medical journal

Investing.com -- Verastem Inc (NASDAQ:VSTM) stock gained 3.5% after the company announced that primary analysis data from its Phase 2 RAMP 201 clinical trial was published in the Journal of Clinical Oncology. The published data showed t... Full story

Yahoo Finance • 3 months ago

Verastem's cancer drug shows 31% response rate in ovarian cancer trial

BOSTON - Verastem Oncology (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $259 million, reported that its combination therapy of avutometinib plus defactinib demonstrated a 31% overall response ra... Full story

Yahoo Finance • 3 months ago

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions... Full story

Yahoo Finance • 4 months ago

Verastem director Gagnon sells $1604 in shares

Verastem, Inc. (NASDAQ:VSTM) Director Robert E. Gagnon sold 284 shares of common stock on June 16, 2025, at a price of $5.65, for a total transaction value of $1604. The transaction comes as VSTM shares have delivered an impressive 60% ret... Full story

Yahoo Finance • 4 months ago

Verastem's SWOT analysis: biotech stock poised for growth amid challenges

Verastem Oncology, Inc. (NASDAQ:VSTM) has recently transitioned into a commercial-stage biopharmaceutical company, marking a significant milestone in its corporate journey. With a market capitalization of $309 million, the company maintain... Full story

Yahoo Finance • 2 years ago

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, June 15, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common st... Full story

Yahoo Finance • 2 years ago

Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged

Verastem could be angling for an accelerated approval of its ovarian cancer treatment, an analyst said Thursday as she upgraded VSTM stock.... Full story

Yahoo Finance • 2 years ago

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 18, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual... Full story

Yahoo Finance • 3 years ago

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Positive Interim Data Read-Out of RAMP 201 and Productive FDA Meeting Support Avutometinib + Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Studies of Avutometinib Combinations in Other RAS Pathway-Driven Canc... Full story

Yahoo Finance • 3 years ago

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 M... Full story